Financial Results

News & Events

Inventiva reçoit un paiement d’étape de 3,5 M€ de la part d’AbbVie

3 décembre 2019

Daix (France), 3 décembre 2019 – Inventiva (Euronext : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale pour le traitement de maladies dans les domaines de la fibrose, de la surcharge lysosomale et de l’oncologie, annonce aujourd’hui la réception d’un paiement d’étape de 3,5 millions d’euros suite à l’inclusion du premier patient atteint de psoriasis dans l’étude clinique en cours avec ABBV-157, un antagoniste RORy découvert conjointement par AbbVie et Inventiva pour le traitement de maladies auto-immunes.

L’étude clinique initiée par AbbVie avec ABBV-157 est une étude randomisée, en double aveugle, avec un contrôle placebo, durant laquelle des patients atteints de psoriasis en plaque chronique modéré à sévère recevront de multiples doses du candidat médicament par voie orale.

Frédéric Cren, Président-directeur général et cofondateur d’Inventiva, a commenté : « Cette étape clé est une excellente nouvelle pour Inventiva, d’autant que nous l’avons franchie beaucoup plus tôt que prévu. Nous sommes ravis des résultats obtenus avec ABBV-157 et très fiers de collaborer avec un partenaire aussi engagé qu’AbbVie, leader mondial dans le domaine des maladies auto-immunes, capable de faire d’ABBV-157 un traitement de référence. »

En 2012, Inventiva et AbbVie ont signé un partenariat pluriannuel de recherche afin d’identifier des antagonistes RORγ pour le traitement de plusieurs maladies auto-immunes. Dans le cadre de cette collaboration, Inventiva met à profit son expertise en matière de découverte et ses plateformes technologiques afin de développer des candidats médicaments visant le récepteur nucléaire RORy, une cible thérapeutique validée pour le traitement des troubles inflammatoires cutanés comme le psoriasis. Dans le domaine des maladies auto-immunes, Inventiva concentre ses activités de recherche et de développement sur des composés qui se distinguent par une posologie améliorée, une plus grande efficacité et potentiellement une meilleure sécurité/tolérance par rapport aux agents biologiques, traitements de référence actuels.

Dans le cadre de cette collaboration, Inventiva reste éligible à de nouveaux paiements d’étape et redevances sur les ventes futures d’ABBV-157.

Contacts

Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Yannick Tetzlaff / Tristan Roquet Montegon

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

LifeSci Advisors
Monique Kosse

Investor relations
monique@lifesciadvisors.com

About Inventiva
Inventiva is a biopharmaceutical company specialized in the development of drugs interacting with nuclear receptors, transcription factors and epigenetic modulators. Inventiva’s research engine opens up novel breakthrough therapies against fibrotic diseases, cancers and orphan diseases with substantial unmet medical needs.

Lanifibranor, its lead product, is an anti-fibrotic treatment acting on the three alpha, gamma and delta PPARs (peroxisome proliferator-activated receptors), which play key roles in controlling the fibrotic process. Its anti-fibrotic action targets two initial indications with substantial unmet medical need: NASH, a severe and increasingly prevalent liver disease already affecting over 30 million people in the United States, and systemic sclerosis, a disease with a very high mortality rate and for which there is no approved treatment to date.

Inventiva is also developing a second clinical program with odiparcil (IVA 336) for the treatment of patients with mucopolysaccaridosis type VI (or Maroteaux-Lamy syndrome), a rare and severe gene disease affecting children. Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome). Inventiva is also developing a portfolio of early research projects in the field of oncology.

Inventiva benefits from partnerships with world-leading research entities such as the Institut Curie in the field of oncology. Two strategic partnerships have also been established with world-class major pharmaceutical companies AbbVie and Boehringer Ingelheim in the fields of autoimmune diseases (specifically in psoriasis) and fibrosis respectively. These partnerships provide milestone payments to Inventiva upon the achievement of pre-clinical, clinical, regulatory and commercial milestones, in addition to royalties on the products resulting from the partnerships.

Inventiva employs over 100 employees and owns R&D facilities near Dijon, acquired from the international pharmaceutical group Abbott. The Company owns, a proprietary chemical library of over 240,000 molecules as well as integrated biology, chemistry, ADME and pharmacology platforms.

Important Notice
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical development
plans, business and regulatory strategy, and anticipated future performance of Inventiva and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management »s beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva »s control.

There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements.

Please refer to the “Document de référence » filed with the Autorité des Marchés Financiers on April 13, 2018 under n° R.18-013 for additional information in relation to such factors, risks and uncertainties.

Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements.